Semaglutide for Alcohol Use Disorder

NCT05520775 ↗

Phase 2 Completed 48 enrolled University of North Carolina, Chapel Hill National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab

RandomizedParallel-groupTriple-blindBasic science

Summary

This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).

Timeline

Start: 2022-09-02
Primary completion: 2024-04-12
Completion: 2024-04-19

Outcome

Met primary endpoint

paper Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task PMID 39937469 ↗

paper grams of alcohol consumed (β, -0.48; 95% CI, -0.85 to -0.11; P = .01) PMID 39937469 ↗

Publications

Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. doi: 10.1001/jamapsychiatry.2024.4789.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	0.5 mg	Subcutaneous